<p>As India gears up to vaccinate over a billion people against the coronavirus, experts dealing with vaccine-related decisions in government are considering making the vaccine available at drugstores for private use, for those who can afford to buy it.</p>.<p>Prices for these privately available vaccines are likely to be subsidised but are subject to regulatory approval from the drug control authorities to a vaccine candidate, an expert working on vaccine-related decision with the government told <a href="https://www.hindustantimes.com/india-news/vaccine-may-be-available-at-pharmacies/story-b7NoAjCmdqN43D5EEOH8AM.html" target="_blank"><em>Hindustan Times</em><strong>.</strong></a></p>.<p>The government is preparing to begin inoculation for the vulnerable population early next year, once a candidate is finalised. It is currently drafting beneficiaries which include about 30 million health and frontline workers. </p>.<p>“This is something that was also done for the influenza vaccine; those who can pay are allowed to access the vaccine in private (market) with certain riders,” a senior official in the government told the publication.</p>.<p>Currently, three candidates -- Pfizer-BioNTech, Serum Institute of India’s Oxford-AstraZeneca, and Bharat Biotech-Indian Council of Medical Research -- have submitted their bids to the national drugs regulator for emergency use authorisation or the EUA. </p>.<p>AIIMS Director, Dr Randeep Guleria, said in an interview that the regulatory approval might come later in the year or by early 2021. </p>.<p>This comes as a relief to the country which continues to be the worst-hit in the world after the United States with over one crore cases and death toll due to the virus nearing 1.47 lakh. </p>
<p>As India gears up to vaccinate over a billion people against the coronavirus, experts dealing with vaccine-related decisions in government are considering making the vaccine available at drugstores for private use, for those who can afford to buy it.</p>.<p>Prices for these privately available vaccines are likely to be subsidised but are subject to regulatory approval from the drug control authorities to a vaccine candidate, an expert working on vaccine-related decision with the government told <a href="https://www.hindustantimes.com/india-news/vaccine-may-be-available-at-pharmacies/story-b7NoAjCmdqN43D5EEOH8AM.html" target="_blank"><em>Hindustan Times</em><strong>.</strong></a></p>.<p>The government is preparing to begin inoculation for the vulnerable population early next year, once a candidate is finalised. It is currently drafting beneficiaries which include about 30 million health and frontline workers. </p>.<p>“This is something that was also done for the influenza vaccine; those who can pay are allowed to access the vaccine in private (market) with certain riders,” a senior official in the government told the publication.</p>.<p>Currently, three candidates -- Pfizer-BioNTech, Serum Institute of India’s Oxford-AstraZeneca, and Bharat Biotech-Indian Council of Medical Research -- have submitted their bids to the national drugs regulator for emergency use authorisation or the EUA. </p>.<p>AIIMS Director, Dr Randeep Guleria, said in an interview that the regulatory approval might come later in the year or by early 2021. </p>.<p>This comes as a relief to the country which continues to be the worst-hit in the world after the United States with over one crore cases and death toll due to the virus nearing 1.47 lakh. </p>